Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Yasmeen Rahimi
PIPR
Yasmeen Rahimi
Piper Sandler
Wall Street Analyst
★☆☆☆☆
#2464
on 13Foresight · ranked by our own returns
34%
Success Rate
-7.0%
Average Return
21 of 61 calls profitable · -16.8% vs benchmark
📈 Across the calls we could measure, roughly 34% of Yasmeen Rahimi's ratings turned a profit when each position was held for 1 year — averaging -7.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

187 Buy 8 Hold 0 Sell
Yasmeen's Stock Coverage 63 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
PRAX
Praxis Precision Medicines
 Jun 18, 2026 BUY Strong Buy
+91.5% avg upside
24 analysts
$1200.00
325.11% Upside
 ·
ROIV
Roivant Sciences
 Jun 16, 2026 BUY Strong Buy
+2.5% avg upside
17 analysts
$40.00
27.25% Upside
 +2.6%
TENX
Tenax Therapeutics
 Jun 12, 2026 BUY Strong Buy
+213.9% avg upside
8 analysts
$50.00
316.71% Upside
 ·
IVA
Inventiva
 Jun 08, 2026 BUY Strong Buy
+350.1% avg upside
16 analysts
$26.00
628.23% Upside
 -7.4%
ORKA
Oruka Therapeutics
 Jun 02, 2026 BUY Strong Buy
+61.8% avg upside
16 analysts
$180.00
148.92% Upside
 +28.3%
UNCY
Unicycive Therapeutics
 Jun 01, 2026 BUY Strong Buy
+708.7% avg upside
10 analysts
$90.00
1213.78% Upside
 ·
IMVT
Immunovant
 May 29, 2026 BUY Strong Buy
+8.9% avg upside
24 analysts
$66.00
86.79% Upside
 +4.2%
KRRO
Korro Bio
 May 28, 2026 BUY Strong Buy
+108.3% avg upside
19 analysts
$30.00
130.94% Upside
 -17.5%
DSGN
Design Therapeutics
 May 27, 2026 BUY Strong Buy
+45.3% avg upside
9 analysts
$20.00
60.68% Upside
 ·
DRUG
Bright Minds Biosciences
 May 20, 2026 BUY Strong Buy
+120.9% avg upside
10 analysts
$220.00
262.74% Upside
 +0.9%
CLYM
Climb Bio
 May 19, 2026 BUY Strong Buy
+57.9% avg upside
18 analysts
$23.00
100.86% Upside
 ·
TECX
Tectonic Therapeutic
 May 18, 2026 BUY Strong Buy
+88.0% avg upside
24 analysts
$76.00
153.10% Upside
 ·
ANAB
AnaptysBio
 May 13, 2026 BUY Strong Buy
+26.1% avg upside
26 analysts
$93.00
61.72% Upside
 -8.1%
LBRX
LB Pharmaceuticals, Inc.
 May 13, 2026 BUY Strong Buy
+50.1% avg upside
7 analysts
$78.00
160.08% Upside
 -13.7%
SVRA
Savara
 May 13, 2026 BUY Strong Buy
+57.8% avg upside
17 analysts
$16.00
190.83% Upside
 -4.5%
NAMS
NewAmsterdam Pharma Company
 May 12, 2026 BUY Strong Buy
+56.4% avg upside
18 analysts
$60.00
101.10% Upside
 -23.3%
PLRX
Pliant Therapeutics
 May 12, 2026 BUY Buy
+1821.1% avg upside
21 analysts
$3.00
158.55% Upside
 +4.2%
ATYR
aTyr Pharma
 May 12, 2026 BUY Buy
+2023.9% avg upside
17 analysts
$20.00
4339.54% Upside
 -1.9%
AVTX
Avalo Therapeutics
 May 11, 2026 BUY Strong Buy
+265.1% avg upside
19 analysts
$60.00
308.09% Upside
 -19.3%
NKTR
Nektar Therapeutics
 May 08, 2026 BUY Buy
+16.5% avg upside
25 analysts
$192.00
214.89% Upside
 -25.6%
ALGS
Aligos Therapeutics
 May 08, 2026 BUY Strong Buy
+773.1% avg upside
11 analysts
$175.00
3214.47% Upside
 -11.3%
CRNX
Crinetics Pharmaceuticals
 May 08, 2026 BUY Strong Buy
+121.2% avg upside
20 analysts
$97.00
170.36% Upside
 -11.2%
PRTA
Prothena
 May 08, 2026 BUY Buy
+160.9% avg upside
14 analysts
$36.00
303.12% Upside
 -20.9%
TNYA
Tenaya Therapeutics
 May 07, 2026 BUY Strong Buy
+1273.8% avg upside
11 analysts
$40.00
5374.89% Upside
 +1.2%
CYTK
Cytokinetics
 May 06, 2026 BUY Strong Buy
+8.9% avg upside
36 analysts
$107.00
35.88% Upside
 +5.5%
NSPR
InspireMD
 May 05, 2026 BUY Strong Buy
+447.3% avg upside
8 analysts
$3.00
322.47% Upside
 -25.8%
TRAX
First Tracks Biotherapeutics Inc
 May 04, 2026 BUY Strong Buy
+113.2% avg upside
7 analysts
$54.00
209.98% Upside
 ·
LXRX
Lexicon Pharmaceuticals
 Apr 15, 2026 BUY Buy
+98.7% avg upside
9 analysts
$6.00
198.50% Upside
 +2.7%
PALI
Palisade Bio
 Apr 13, 2026 BUY Strong Buy
+1347.1% avg upside
15 analysts
$25.00
1236.91% Upside
 -11.6%
STTK
Shattuck Labs
 Apr 13, 2026 BUY Strong Buy
+369.1% avg upside
14 analysts
$15.00
202.93% Upside
 -36.0%
UPB
Upstream Bio, Inc.
 Apr 02, 2026 BUY Strong Buy
+514.9% avg upside
9 analysts
$75.00
1099.98% Upside
 -32.1%
ZURA
Zura Bio
 Apr 01, 2026 BUY Strong Buy
+289.3% avg upside
12 analysts
$26.00
593.37% Upside
 -41.7%
TVRD
Tvardi Therapeutics
 Apr 01, 2026 HOLD Buy
+585.4% avg upside
23 analysts
$3.00
14.15% Upside
 +10.0%
GOSS
Gossamer Bio
 Mar 18, 2026 BUY Buy
+4379.4% avg upside
17 analysts
$15.00
8828.51% Upside
 -20.9%
ARCT
Arcturus Therapeutics
 Mar 04, 2026 BUY Buy
+290.9% avg upside
35 analysts
$25.00
232.06% Upside
 +10.8%
GPCR
Structure Therapeutics, Inc. Sponsored ADR
 Feb 27, 2026 BUY Strong Buy
+132.5% avg upside
17 analysts
$93.00
109.00% Upside
 -41.9%
BIOA
BioAge Labs, Inc.
 Feb 13, 2026 BUY Strong Buy
+138.3% avg upside
9 analysts
$73.00
251.42% Upside
 -9.8%
EWTX
Edgewise Therapeutics
 Feb 09, 2026 BUY Strong Buy
+22.4% avg upside
14 analysts
$51.00
38.48% Upside
 +12.2%
MDGL
Madrigal Pharmaceuticals
 Jan 13, 2026 BUY Strong Buy
-5.8% avg upside
31 analysts
$900.00
77.92% Upside
 -2.7%
BNTC
Benitec Biopharma
 Sep 24, 2025 BUY Strong Buy
+118.1% avg upside
13 analysts
$30.00
146.87% Upside
 -18.4%
ALT
Altimmune
 Jun 27, 2025 BUY Strong Buy
+935.8% avg upside
19 analysts
$25.00
825.91% Upside
 -17.1%
SGMT
Sagimet Biosciences, Inc. Class A
 Jun 17, 2025 BUY Strong Buy
+317.2% avg upside
15 analysts
$67.00
902.91% Upside
 +0.3%
IMUX
Immunic
 Mar 20, 2025 BUY Strong Buy
+166.0% avg upside
21 analysts
$28.00
97.23% Upside
 -3.5%
OKUR
OnKure Therapeutics
 Dec 14, 2023 HOLD Buy
+428.3% avg upside
12 analysts
$40.00
792.95% Upside
 -26.4%
PTGX
Protagonist Therapeutics
 Jul 05, 2023 BUY Strong Buy
-22.1% avg upside
19 analysts
$35.00
68.90% Downside
 +44.2%
ENTA
Enanta Pharmaceuticals
 May 09, 2023 BUY Buy
+159.2% avg upside
17 analysts
$87.00
587.12% Upside
 -49.3%
MIRM
Mirum Pharmaceuticals
 May 08, 2023 BUY Strong Buy
+7.0% avg upside
21 analysts
$77.00
28.20% Downside
 -5.0%
AMRN
Amarin
 Mar 15, 2022 BUY Buy
-47.3% avg upside
18 analysts
$19.00
18.59% Upside
 -47.0%
VXRT
Vaxart
 Feb 28, 2022 BUY Strong Buy
+1315.6% avg upside
8 analysts
$18.00
3166.88% Upside
 -84.7%
GREE
Greenidge Generation Holdings
 Oct 12, 2021 HOLD Hold
+513.4% avg upside
5 analysts
 — ·
MTNB
Matinas BioPharma
 Sep 13, 2021 HOLD Buy
+2193.0% avg upside
7 analysts
$0.90
48.99% Upside
 -32.4%
MRNA
Moderna
 Jun 03, 2020 BUY Hold
+6.1% avg upside
38 analysts
$68.00
6.30% Upside
 +226.0%
DARE
Daré Bioscience
 May 15, 2020 BUY Strong Buy
+516.8% avg upside
14 analysts
$4.00
84.36% Upside
 +27.5%
GLMD
Galmed Pharmaceuticals
 May 14, 2020 BUY Buy
+4113.3% avg upside
13 analysts
$33.00
5589.62% Upside
 -53.4%
TPST
Tempest Therapeutics
 May 08, 2020 BUY Buy
+1669.9% avg upside
18 analysts
$6.00
387.80% Upside
 -32.3%
HEPA
Hepion Pharmaceuticals
 Mar 20, 2020 BUY Strong Buy
+82042.8% avg upside
9 analysts
$9.00
14900.05% Upside
 ·
FR:GNFT
Genfit
 Dec 19, 2019 BUY Strong Buy
+181.4% avg upside
5 analysts
$70.00
556.66% Upside
 ·
EVFM
Evofem Biosciences
 Dec 18, 2019 BUY Buy
+269017.6% avg upside
8 analysts
$12.00
141076.41% Upside
 ·
LRMR
Larimar Therapeutics
 Sep 06, 2019 HOLD Strong Buy
+409.3% avg upside
21 analysts
 — +46.7%
SEELQ
Seelos Therapeutics
 Aug 02, 2019 BUY Buy
+46385614.3% avg upside
10 analysts
$8.00
7999900.05% Upside
 -23.2%
MTVA
MetaVia
 Aug 10, 2018 HOLD Strong Buy
+1769.3% avg upside
13 analysts
$2.00
25.01% Upside
 -62.5%
VYNE
VYNE Therapeutics
 Jul 24, 2018 BUY Strong Buy
+2024.6% avg upside
9 analysts
$29.00
4464.08% Upside
 -46.2%
GALT
Galectin Therapeutics
 Jan 04, 2018 BUY Strong Buy
+245.1% avg upside
8 analysts
$8.00
183.11% Upside
 -4.9%
🔒 58 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Yasmeen Rahimi — Frequently Asked Questions
How accurate are Yasmeen Rahimi's stock ratings?
Based on the calls 13Foresight could measure, about 34% of Yasmeen's ratings were profitable over a one-year hold, with an average return of -7.0% per rating, or -16.7% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Yasmeen ranked on 13Foresight?
Yasmeen Rahimi is currently ranked #2464 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Yasmeen cover?
Yasmeen most recently has ratings on PRAX, ROIV, TENX, IVA, ORKA, UNCY, IMVT, KRRO, DSGN, DRUG, CLYM, TECX and 51 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.